ASCO submitted comments to the Centers for Medicare & Medicaid Services (CMS) in response to “CMS Patient Relationship Categories and Codes,” a document in which the agency proposes a framework for attributing care costs to specific providers, called the Quality Payment Program (QPP), as required under the Medicare Access and CHIP Reauthorization Act (MACRA). In addition to answering specific questions posed by CMS in the document, ASCO's comments focus on the importance of transparency around how CMS plans to integrate the patient relationship categories and codes into the QPP and the need for further refinement of the proposed categories and codes to ensure accurate attribution for oncology care.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
The Food and Drug Administration (FDA) has announced efforts to help mitigate the shortage of Bleomycin Sulfate for Injection. The agency will be coordinating with Amneal Bioscience to import its Bleomycin Sulfate Powder for Injection, which contains the same active ingredients as the FDA-approved Bleomycin Sulfate for Injection.
ASCO recently posted a new policy brief, Minimum Legal Age for Purchase of Tobacco Products, in support of increasing the minimum legal age of purchase of tobacco products to 21 years of age.
On August 8, the Food and Drug Administration’s (FDA) rule giving the agency the authority to regulate E-cigarettes, cigars, hookah and pipe tobacco, took effect.
ASCO has confirmed that CMS is currently working to correct technical errors that occurred when they recently updated national coverage policies regarding certain genetic tests.
A new article published in the Journal of Oncology Practice (JOP) shares the results of new office procedures at a private practice in Michigan that were implemented to improve patient management of symptoms in oral oncolytic care.
CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO, has announced an exciting new benefit for practices participating in CancerLinQ™. Current and future early adopters of CancerLinQ who sign up before ASCO’s 2017 Annual Meeting will receive a complimentary subscription to ASCO University Essentials which includes access to ASCO University eLearning catalog, ASCO’s Personalized Learning Dashboard, and ASCO’s MOC App.
A foreword by Joseph O. Jacobson, MD, MSc, Craig Earle, MD, MSc, and Michael Neuss, MD, in the Journal of Oncology Practice (JOP) shares the highlights and impact of the fourth American Society of Clinical Oncology (ASCO) Quality Care Symposium (QCS) and looks ahead to next year’s symposium and how it can benefit all oncology professionals.
On August 16, the Journal of Oncology Practice (JOP) published a joint guidance statement from ASCO and the American Academy of Hospice and Palliative Medicine (AAHPM) regarding high-quality palliative care as delivered directly by medical oncology practices themselves.
ASCO is supporting an important public workshop sponsored by the U.S. Food and Drug Administration (FDA) to address the issue of cardiovascular toxicities within oncology clinical trials.
ASCO met with the Department of Health and Human Services (HHS) on proposed changes to the Common Rule, which is undergoing its first revision in 30 years. ASCO reiterated its support for many proposed changes and reiterated its concerns with several areas, including the proposal to classify all biospecimens as "human subjects."
On August 5, 2016, the U. S. Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA® injection, Merck Sharp & Dohme Corp.) for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy.
The U.S. Food and Drug Administration (FDA) is currently seeking applicants for its FDA Patient Representative Program for several disease areas, including cardiovascular disease, sarcoma, thyroid and bladder cancer.
ASCO members hosted Representative Joe Barton at the MD Anderson Cancer Center to discuss key cancer care issues.